Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Esophageal Neoplasms 3Esophageal Squamous Cell Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

pembrolizumab 90Blood Specimen Collection 44Cyclophosphamide 37Nivolumab 35Bevacizumab 35Standard of Care 32Carboplatin 30Surveys and Questionnaires 29Paclitaxel 28atezolizumab 24Pemetrexed 24Gemcitabine 24Exercise 24Fluorouracil 23Cisplatin 23Leucovorin 21Dexamethasone 20Radiotherapy 19Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Ipilimumab 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Drug Therapy 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × TP protocol × 1 year × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡